BIONTECH SE SPON. ADRS 1
Commented by Nico Popp on November 24th, 2021 | 12:41 CET
BioNTech, Defence Therapeutics, Novavax: Another step towards vaccination against cancer
In Portugal and Spain, vaccination rates are higher than in Germany. There are various discussions about the reasons for this. One argument is the fact that infant mortality was high in both countries for a long time. Those who still vividly remember the stories of dead or lifelong damaged infants are less likely to think twice when the doctor calls for vaccination. The recent experience with BioNTech and other vaccines could also give a new boost to the willingness to vaccinate. It is, therefore, quite fitting that vaccines against many different diseases are now emerging on the market.
Read
Commented by André Will-Laudien on November 10th, 2021 | 11:25 CET
Pfizer, BioNTech, Water Ways Technologies, Teva Pharma - High-Tech and the Pandemic!
Shortly after the start of the worldwide vaccination campaigns, Israel already showed itself to be the vaccination world champion. This is no coincidence because Israel is a high-tech country and one of the world leaders. The medical infrastructure, in particular, can benefit from this; it is very well developed and, despite the comparatively small size of the state, is considered to be very resilient. The pandemic has nevertheless hit hard on Israel's economy, which previously grew at rates of 3% annually. In 2020, GDP fell by 3.7%, according to the central bank. That things didn't get worse was due to the large government aid packages. These packages increased government debt from 60 to 73% of GDP, which is still low by global standards. We take a look at some exciting technology topics.
Read
Commented by André Will-Laudien on November 8th, 2021 | 12:08 CET
BioNTech, Moderna, Cardiol Therapeutics, Valneva: COVID-19, the vaccination chaos is perfect!
Now the chaos is perfect. According to studies, the preparation from BioNTech/Pfizer is one of the most effective vaccines against the coronavirus. Hundreds of millions of doses have already been administered worldwide. However, the number of COVID infections is currently through the roof. Even those who have been vaccinated twice are likely still not sufficiently protected against infection. There are also unsettling rumors from BioNTech about irregularities in the conduct of studies during the vaccine's approval. Whether it concerns thereby only "rumors" or "provable facts", the capital investors do not care for the time being. They pressed the sell button and thus sent the entire peer group Adhoc into the basement. We take a closer look at the chaos.
Read
Commented by Stefan Feulner on November 5th, 2021 | 11:22 CET
BioNTech, Sativa Wellness, Merck KGaA - Impressive trend
There is no question that vaccine manufacturers are one of the main winners of the Corona pandemic. The recently presented quarterly figures of Pfizer, BioNTech's partner, show this impressively and suggest that the Mainz-based Company will also announce a sales explosion on November 9. Booster vaccinations are likely to continue this trend. Currently, encouraged by legalization, the cannabis industry is also experiencing a new upswing. Be a part of it from the beginning.
Read
Commented by Stefan Feulner on November 3rd, 2021 | 10:16 CET
Valneva, Cardiol Therapeutics, BioNTech - Is the vaccination subscription coming?
The numbers of people infected with Corona have been rising significantly again for weeks. While only about 67% of Germans are fully vaccinated, the pace is slowing noticeably. Meanwhile, the third dose, the so-called "booster" vaccination, has already been started. The Standing Commission on Vaccination (STIKO) has recommended this booster for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is likely to be made soon. For vaccine manufacturers, this means recurring revenues.
Read
Commented by Armin Schulz on November 1st, 2021 | 11:15 CET
BioNTech, Memiontec, TeamViewer - Which high flyers still have potential?
High flyers are companies that establish themselves very quickly in a market or shares that increase in value very quickly. As an investor, one dreams of such investments. A stock that gains more than 100% in value within months is often found in extreme situations and when hypes arise. At some point, the situation normalizes, or the hype ends because not enough investors jump on the bandwagon. A drastic consolidation often follows that. Today, we analyze three companies whose shares have gained at least 200% since the Corona pandemic and look at their future potential.
Read
Commented by Nico Popp on October 18th, 2021 | 10:44 CEST
BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon
The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.
Read
Commented by André Will-Laudien on October 14th, 2021 | 11:27 CEST
BioNTech, Cardiol Therapeutics, CureVac: A decade's worth of ideas!
Biotechnology remains a hotly contested industry. In the fight against a wide range of diseases, biopharmaceuticals are the first port of call. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. By directly applying findings from biology and biochemistry, technically functional elements are identified. The central objectives are to research, improve and develop processes for the production of relevant substances. Often research goes nowhere; we take a look at the sector.
Read
Commented by Carsten Mainitz on October 12th, 2021 | 12:32 CEST
Defence Therapeutics, BioNTech, Valneva - When will things pick up again?
Biotechnology companies can experience a significant, sometimes even exponential, increase in value virtually overnight with a new, successful active ingredient. BioNTech is a prime example of this. But not every research effort leads to success, and CureVac shareholders can tell you a thing or two about that. Canada's Defence Therapeutics and Valneva have innovative research pipelines. Where should investors consider investing now?
Read
Commented by André Will-Laudien on October 8th, 2021 | 10:25 CEST
BioNTech, Defence Therapeutics, Valneva, Formycon - Close to the bio-revolution!
Portugal is one of the countries with the highest vaccination rate, with 86% of the population already vaccinated. Approximately 98% of those eligible for vaccination - including everyone over the age of 12 - have been vaccinated. Germany, with about 64%, is one of the more vaccine-weary nations. What is the secret of the Portuguese? The government relied on an opinion maker from within its ranks, Admiral Gouveia e Melo. An expert in complicated logistical tasks in the military, he was appointed in February as the top leader of the national vaccination campaign. He is never seen without his military combat uniform in numerous public television appearances - and when asked how other countries can move their own vaccination effort forward, the admiral did not hesitate to offer his best advice: "You have to find people who are not politicians." Where are the current opportunities in the vaccination sector?
Read